Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists

被引:1
|
作者
Joshi, Jayadev [1 ,2 ]
Dimri, Manali [1 ]
Ghosh, Subhajit [1 ,2 ]
Shrivastava, Nitisha [1 ]
Chakraborti, Rina [3 ]
Sehgal, Neeta [3 ]
Ray, Jharna [2 ]
Kumar, Indracanti Prem [1 ]
机构
[1] Inst Nucl Med & Allied Sci, Radiat Biosci Div, Delhi 110054, India
[2] Univ Calcutta, SN Pradhan Ctr Neurosci, Kolkata, India
[3] Univ Delhi, Dept Zool, Delhi 110007, India
关键词
beta; 2AR; beta blocker; cluster analysis; docking; GPCR; SAR; screening; MOLECULAR DOCKING; PREDICTION; AGONISTS; DESIGN; STATE;
D O I
10.2174/1573409911666150812130420
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ligand bound beta 2 adrenergic receptor (beta 2AR) crystal structures are in use for screening of compound libraries for identifying inducers and blockers. However, in case of G protein coupled receptors (GPCR), docking and binding energy (BE) calculations are not enough to discriminate agonist and antagonists. Absence of a reliable model for discriminating beta 2AR antagonist is still a major hurdle. Docking of known antagonists and agonists into activated and ground state beta 2AR revealed several key intermolecular interactions and H-bonding patterns, which in combination, emerged as a model for prediction of antagonists. Present study identifies an alternative binding orientation, within the binding pocket, for blockers and a minimum grid size to lessen the false positive predictions. Cluster analysis revealed structural variability among the antagonists and a conserved pattern in case of agonists. A combination of docking and structure activity relationship (SAR) model reliably discriminated antagonists. Based on key intermolecular interactions, a set of agonists and antagonists useful to SAR, quantitative structure activity relationship (QSAR) and pharmacophore modeling, has also been proposed for identifying antagonists.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 50 条
  • [1] Ligand and Structure-Based Models for the Prediction of Ligand-Receptor Affinities and Virtual Screenings: Development and Application to the β2-Adrenergic Receptor
    Vilar, Santiago
    Karpiak, Joel
    Costanzi, Stefano
    JOURNAL OF COMPUTATIONAL CHEMISTRY, 2010, 31 (04) : 707 - 720
  • [2] The Principles of Ligand Specificity on beta-2-adrenergic receptor
    H. C. Stephen Chan
    Slawomir Filipek
    Shuguang Yuan
    Scientific Reports, 6
  • [3] The Principles of Ligand Specificity on beta-2-adrenergic receptor
    Chan, H. C. Stephen
    Filipek, Slawomir
    Yuan, Shuguang
    SCIENTIFIC REPORTS, 2016, 6
  • [4] CARDIOVASCULAR PHARMACOLOGY OF 2 NEW BETA-ADRENERGIC RECEPTOR ANTAGONISTS
    STANTON, HC
    KIRCHGESSNER, T
    PARMENTER, K
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1965, 149 (02): : 174 - +
  • [5] Analysis of hydrophobic interactions of antagonists with the beta2-adrenergic receptor
    Novoseletsky, V. N.
    Pyrkov, T. V.
    Efremov, R. G.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2010, 21 (1-2) : 37 - 55
  • [6] NEGATIVE ANTAGONISTS PROMOTE AN INACTIVE CONFORMATION OF THE BETA(2)-ADRENERGIC RECEPTOR
    SAMAMA, P
    PEI, G
    COSTA, T
    COTECCHIA, S
    LEFKOWITZ, RJ
    MOLECULAR PHARMACOLOGY, 1994, 45 (03) : 390 - 394
  • [7] IDENTIFICATION OF RESIDUES REQUIRED FOR LIGAND-BINDING TO THE BETA-ADRENERGIC-RECEPTOR
    STRADER, CD
    SIGAL, IS
    REGISTER, RB
    CANDELORE, MR
    RANDS, E
    DIXON, RAF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (13) : 4384 - 4388
  • [8] Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
    Li, Huifang
    Ren, Xin
    Leblanc, Eric
    Frewin, Kate
    Rennie, Paul S.
    Cherkasov, Artem
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (01) : 123 - 130
  • [9] EVOLVING PROPERTIES OF BETA-ADRENERGIC-RECEPTOR ANTAGONISTS
    MOLINOFF, PB
    PHARMACOTHERAPY, 1992, 12 (02): : 144 - 153
  • [10] OXAZOLIDINE DERIVATIVES OF ADRENERGIC BETA-RECEPTOR ANTAGONISTS
    ALMIRANTE, L
    MURMANN, W
    FARMACO-EDIZIONE SCIENTIFICA, 1969, 24 (08): : 744 - +